Odey Asset Management Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Odey Asset Management Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-550,867	Closed	-$2.92M	–	78
2021 Q1	$2.92M	Buy	+550,867	New	+$3.15M	0.82%	28

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Odey Asset Management Group's ADAP Position: Q2 2021 in Review

Odey Asset Management Group sold out of Adaptimmune Therapeutics (ADAP) in Q2 2021, closing a stake of 550,867 shares — an estimated $2.92M sold.

Odey Asset Management Group first reported a position in ADAP in Q1 2021 and held it in 1 quarter. The position peaked at $2.92M in Q1 2021. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

Odey Asset Management Group reported no remaining Adaptimmune Therapeutics position as of Q2 2021 after selling out during the quarter.
Odey Asset Management Group sold 550,867 Adaptimmune Therapeutics shares in Q2 2021, an estimated $2.92M.
Odey Asset Management Group first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 1 quarter.
Odey Asset Management Group's Adaptimmune Therapeutics position peaked at $2.92M in Q1 2021.
82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on Odey Asset Management Group's 13F filing for Q2 2021, filed 16 Aug 2021.